Ultime notizie per AbbVie (NYSE:ABBV) Azioni

AbbVie

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).

AbbVie Inc

ABBVIE ORD

AbbVie's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) short percent of float has fallen 8.18% since its last report. The company recently reported that it has 17.79 million shares sold short, which is 1.01% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.9 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>AbbVie Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727469922_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for AbbVie has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing AbbVie's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, AbbVie's peer group average for short interest as a percentage of float is 5.98%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

ABBV

(ABBV) - Analyzing AbbVie's Short Interest

On Thursday, the FDA approved&nbsp;Bristol Myers Squibb&nbsp;&amp; Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)&nbsp;Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41064867/schizophrenia-treatment-revolution-fda-approves-bristol-myers-squibb-cobenfy-as-new-class-of-trea" rel="noreferrer noopener">schizophrenia in adults</a>.
BMO Capital analyst notes that the FDA approval without a boxed warning is a significant positive for Bristol Myers shares.
The analyst notes that given that many prior antipsychotic medications received black box warnings due to increased mortality risks, particularly in elderly patients, Cobenfy&#8217;s absence of such a warning could significantly enhance its potential in treating Alzheimer&#8217;s related-psychosis, pending further clinical trials.
BMO projects peak sales of $2.4 billion for Cobenfy in schizophrenia and $3.9 billion in Alzheimer&#8217;s related-psychosis, raising the price target to $53 from $48, with a <a target="_blank" href="https://www.benzinga.com/quote/BMY/analyst-ratings" rel="noreferrer noopener">Market Perform rating</a>.
The analyst notes that Cobenfy will be priced at $1,850 for a 30-day supply or $22,500/year, representing a discount to previous expectations.
Truist Securities highlights that AbbVie Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) is also advancing emraclidine as a treatment for schizophrenia and Alzheimer&#8217;s disease-related psychosis.
According to Truist analysts, emraclidine differs from KarXT in its mechanism of action.
Despite emerging competition, Truist points out that KarXT holds a first-mover advantage and is ahead by at least two to three years.
Truist maintains the Buy rating and a price target of $62.
William Blair projects peak U.S. sales for Cobenfy to reach approximately $2 billion by 2030, driven solely by its use in treating schizophrenia.
However, if the drug is approved for additional indications, such as Alzheimer-related psychosis and adjunctive schizophrenia—both currently in Phase 3 trials—annual sales could rise to around $3 billion to $5 billion, pending positive results.
The analyst points out that although the label lacks a black box warning, it does include caution for urinary retention, elevated heart rate, reduced gastric motility, and angioedema.
Price Action: BMY stock is up 2.33% at $51.29&nbsp;at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/41070911/fda-removes-clinical-hold-on-biomea-fusions-early-stage-trials-for-potential-diabetes-candidate" target="_blank" rel="noreferrer noopener">FDA Removes Clinical Hold On Biomea Fusion&#8217;s Early-Stage Trials For Potential Diabetes Candidate</a>.</li>
</ul>

Analyst Color

Biotech

Large Cap

News

Health Care

Price Target

Analyst Ratings

Movers

General

Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential

- Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression.
- Biologics License Application (BLA) submission for accelerated approval is supported by data from the Phase 2 LUMINOSITY trial (M14-239). Review of the BLA will be conducted under FDA's Oncology Center of Excellence (OCE) Real-Time Oncology Review (RTOR) program.&nbsp;
- There are currently no approved anti-cancer therapies specifically for c-Met overexpressing NSCLC and if approved Teliso-V would be the first-in-class therapy for this patient population.&nbsp;
NORTH CHICAGO, Ill., Sept. 27, 2024 /PRNewswire/ --&nbsp;AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) today announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for accelerated approval of telisotuzumab vedotin (Teliso-V) in adult patients with previously treated, locally advanced or metastatic epidermal growth factor receptor (EGFR) wild type, nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression.
Approximately 85% of lung cancers are classified as NSCLC1&nbsp;and despite advances in treatment, lung cancer remains the leading cause of cancer-related deaths throughout the world.2&nbsp;The c-Met protein is a receptor tyrosine kinase found to be overexpressed in approximately 25% of advanced EGFR wild type, nonsquamous NSCLC patients3&nbsp;and is associated with a poor prognosis.4,5,6 Teliso-V is being evaluated within this patient population who currently have very limited treatment options.&nbsp;

AbbVie Submits Biologics License Application To The FDA For Telisotuzumab Vedotin In Previously Treated Non-Small Cell Lung Cancer

AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) has outperformed the market over the past 10 years by 1.46% on an annualized basis producing an average annual return of 12.86%. Currently, AbbVie has a market capitalization of $338.87 billion. 
Buying $1000 In ABBV: If an investor had bought $1000 of ABBV stock 10 years ago, it would be worth $3,322.37 today based on a price of $191.90 for ABBV at the time of writing.
<h3>AbbVie's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727386222_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years

On Thursday, AbbVie&nbsp;Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) released topline results from its pivotal Phase 3 TEMPO-1 trial for tavapadon as a monotherapy in <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/n41044273/abbvie-announces-positive-topline-results-from-phase-3-tempo-1-trial-evaluating-tavapadon-as-a-mon" rel="noreferrer noopener">early Parkinson&#8217;s disease</a>.
Tavapadon is an investigational D1/D5 dopamine receptor partial agonist being studied as a once-daily treatment for Parkinson&#8217;s disease. AbbVie added the drug candidate with its $8.7 billion&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36138732/abbvies-new-9b-neuroscience-space-deal-might-attract-ftc-scrutiny-analyst-signals" rel="noreferrer noopener">buyout of Cerevel Therapeutics</a>.
The TEMPO-1 trial evaluated the efficacy, safety and tolerability of two fixed doses (5 mg and 15 mg, once daily) of tavapadon as a monotherapy in adults with early Parkinson&#8217;s disease.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40820758/unitedhealth-follows-competitors-replaces-humira-with-lower-cost-biosimilars" rel="noreferrer noopener">UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars</a>.
The trial met its primary endpoint – patients treated with tavapadon in both dose groups experienced a statistically significant reduction (improvement) from baseline compared to placebo (placebo: +1.8; 5 mg: -9.7; 15 mg: -10.2 versus placebo) in the Movement Disorder Society &#8211; Unified Parkinson&#8217;s Disease Rating Scale (MDS-UPDRS) Parts II and III combined score at week 26.
MDS-UPDRS assesses motor and non-motor symptoms of Parkinson&#8217;s disease.
The TEMPO-1 trial also met the key secondary endpoint, demonstrating a statistically significant and clinically meaningful improvement in motor aspects of experiences of daily living (MDS-UPDRS Part II) in both tavapadon dose groups compared to placebo at week 26.
The safety profile observed in the TEMPO-1 trial was consistent with prior clinical trials. The majority of adverse events reported were mild to moderate in severity.
Full results from the TEMPO-1 study will be submitted for presentation at future medical meetings and used to support regulatory submissions of tavapadon as a treatment for Parkinson&#8217;s disease.
Topline results from TEMPO-2, the Phase 3 flexible-dose monotherapy trial for tavapadon, are expected by the end of 2024.
Price Action: ABBV stock is up 0.33% at $191.90 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/41048142/visa-takes-on-financial-crime-acquires-ai-fraud-specialist-featurespace-strengthening-payment-se" target="_blank" rel="noreferrer noopener">Visa Takes On Financial Crime: Acquires AI Fraud Specialist Featurespace, Strengthening Payment Security</a>.</li>
</ul>
Photo via Shutterstock

AbbVie Says Pivotal Trial For Parkinson's Candidate Meets Its Primary Goal In Patients With Early Disease

AbbVie Announces Phase 3 TEMPO-1 Trial Results For Tavapadon As Monotherapy In Early Parkinson's Disease, Showing Significant Improvement In MDS-UPDRS Scores; Results From TEMPO-2 Flexible-Dose Trial Expected By Year-End 2024

AbbVie Announced Results From A New Post-Hoc Analysis From The Measure Up 1 And Measure Up 2 Phase 3 Studies Of Upadacitinib (15 mg Or 30 mg) In Patients With Moderate-to-severe Atopic Dermatitis

Whales with a lot of money to spend have taken a noticeably bearish stance on AbbVie.
Looking at options history for AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) we detected 15 trades.
If we consider the specifics of each trade, it is accurate to state that 33% of the investors opened trades with bullish expectations and 40% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $199,317 and 13, calls, for a total amount of $651,450.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $165.0 to $210.0 for AbbVie during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of AbbVie stands at 941.86, with a total volume reaching 2,530.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in AbbVie, situated within the strike price corridor from $165.0 to $210.0, throughout the last 30 days.
<h3>AbbVie 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727202645_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$12.2</td>
<td>$12.0</td>
<td>$11.98</td>
<td>$195.00</td>
<td>$150.3K</td>
<td>559</td>
<td style="text-align: right;">291</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$9.2</td>
<td>$9.15</td>
<td>$9.18</td>
<td>$200.00</td>
<td>$108.8K</td>
<td>1.5K</td>
<td style="text-align: right;">237</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.73</td>
<td>$2.7</td>
<td>$2.73</td>
<td>$210.00</td>
<td>$96.7K</td>
<td>354</td>
<td style="text-align: right;">377</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$13.1</td>
<td>$12.95</td>
<td>$13.06</td>
<td>$185.00</td>
<td>$84.7K</td>
<td>3.1K</td>
<td style="text-align: right;">70</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$25.9</td>
<td>$25.5</td>
<td>$25.5</td>
<td>$170.00</td>
<td>$66.3K</td>
<td>550</td>
<td style="text-align: right;">36</td>
</tr>
</tbody>
</table>

<h3>About AbbVie</h3>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
<h3>Where Is AbbVie Standing Right Now?</h3>
<ul>
<li>With a trading volume of 1,696,972, the price of ABBV is down by -0.11%, reaching $193.61.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 31 days from now.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for AbbVie with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

Behind the Scenes of AbbVie's Latest Options Trends

The experimental drug KarXT, developed by Karuna Therapeutics, is expected to receive FDA approval later this month (Sept. 26), marking a significant breakthrough in schizophrenia treatment.
If approved, KarXT would become the first novel schizophrenia drug in over 70 years, offering new hope for patients and medical professionals alike.
Schizophrenia, a mental disorder that affects approximately 3.8 million adults in the U.S., is often characterized by severe symptoms such as social isolation, memory issues and psychotic episodes.
Last year, Bristol-Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) acquired Karuna Therapeutics for $330 per share in cash for a total equity value of $14 billion, or $12.7 billion net of <a href="https://www.benzinga.com/markets/equities/23/12/36388646/bristol-myers-acquisition-of-karuna-therapeutics-paves-way-for-aggressive-global-marketing-of-ka" target="_blank" rel="noreferrer noopener">estimated cash acquired</a>. 
The Financial Times <a target="_blank" href="https://www.ft.com/content/427d37df-e2e9-4b67-87be-29f2a258de00" rel="noreferrer noopener">highlights</a> that existing treatments, mainly focused on blocking dopamine receptors, often come with serious side effects, including weight gain and involuntary movements.
Despite the enthusiasm surrounding KarXT, the complexity and financial constraints of the U.S. health care system could limit access to this new treatment.
High drug pricing could also hinder access; the Institute for Clinical and Economic Review has suggested KarXT be priced at up to $20,000 per year.
In August, AbbVie Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) completed the acquisition of Cerevel Therapeutics, another company focused on developing drugs for neurological disorders, for a total equity value of approximately $8.7 billion, or <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36138732/abbvies-new-9b-neuroscience-space-deal-might-attract-ftc-scrutiny-analyst-signals" rel="noreferrer noopener">$45 per share in cash</a>.
The challenges extend beyond the cost and availability of medications, the Financial Times report adds. Many individuals with mental health conditions, particularly schizophrenia, encounter law enforcement rather than health care professionals during crises.
While KarXT&#8217;s approval could represent a crucial step forward, many experts, including Michael Thompson, a criminal justice expert, say that more systemic changes are needed to ensure mental health care is accessible and effective, especially for vulnerable populations like the homeless, according to FT. 

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40963228/zevra-therapeutics-drug-becomes-first-fda-approved-treatment-for-ultra-rare-neurodegenerative-dis" target="_blank" rel="noreferrer noopener">Zevra Therapeutics&#8217; Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease</a></li>
</ul>
Photo via Pixabay.

Bristol-Myers Acquired Drug KarXT Poised For FDA Approval As First New Type Of Schizophrenia Treatment In 70 Years

Financial giants have made a conspicuous bullish move on AbbVie. Our analysis of options history for AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) revealed 8 unusual trades.
Delving into the details, we found 37% of traders were bullish, while 12% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $325,314, and 4 were calls, valued at $527,350.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $165.0 to $195.0 for AbbVie during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for AbbVie's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of AbbVie's whale trades within a strike price range from $165.0 to $195.0 in the last 30 days. 
<h3>AbbVie Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726859359_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$28.4</td>
<td>$27.15</td>
<td>$28.0</td>
<td>$165.00</td>
<td>$361.2K</td>
<td>1.4K</td>
<td>29</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$3.8</td>
<td>$3.7</td>
<td>$3.71</td>
<td>$180.00</td>
<td>$204.0K</td>
<td>8</td>
<td>553</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$8.1</td>
<td>$8.05</td>
<td>$8.1</td>
<td>$195.00</td>
<td>$101.2K</td>
<td>363</td>
<td>125</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/20/24</td>
<td>$2.12</td>
<td>$1.83</td>
<td>$1.95</td>
<td>$195.00</td>
<td>$58.5K</td>
<td>3.3K</td>
<td>1.0K</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$18.25</td>
<td>$17.75</td>
<td>$17.98</td>
<td>$190.00</td>
<td>$35.9K</td>
<td>646</td>
<td>20</td>
</tr>
</tbody>
</table>

<h3>About AbbVie</h3>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Following our analysis of the options activities associated with AbbVie, we pivot to a closer look at the company's own performance.
<h3>Current Position of AbbVie</h3>
<ul>
<li>With a trading volume of 3,370,211, the price of ABBV is down by -0.39%, reaching $192.86.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 35 days from now.</li>
</ul>
<h3>Expert Opinions on AbbVie</h3>
In the last month, 1 experts released ratings on this stock with an average target price of $209.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Piper Sandler keeps a Overweight rating on AbbVie with a target price of $209. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for AbbVie with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Spotlight on AbbVie: Analyzing the Surge in Options Activity

In today's rapidly changing and highly competitive business world, it is vital for investors and industry enthusiasts to carefully assess companies. In this article, we will perform a comprehensive industry comparison, evaluating AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) against its key competitors in the Biotechnology industry. By analyzing important financial metrics, market position, and growth prospects, we aim to provide valuable insights for investors and shed light on company's performance within the industry.
<h3>AbbVie Background</h3>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
<table>
<thead>
<tr>
<th>Company</th>
<th>P/E</th>
<th>P/B</th>
<th>P/S</th>
<th>ROE</th>
<th>EBITDA (in billions)</th>
<th>Gross Profit (in billions)</th>
<th>Revenue Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>AbbVie Inc</td>
<td>64.53</td>
<td>50.28</td>
<td>6.22</td>
<td>18.4%</td>
<td>$5.0</td>
<td>$10.26</td>
<td>4.31%</td>
</tr>
<tr>
<td>Amgen Inc</td>
<td>57.40</td>
<td>30.19</td>
<td>5.81</td>
<td>13.63%</td>
<td>$3.0</td>
<td>$5.15</td>
<td>20.07%</td>
</tr>
<tr>
<td>Regeneron Pharmaceuticals Inc</td>
<td>30.15</td>
<td>4.45</td>
<td>9.66</td>
<td>5.19%</td>
<td>$1.76</td>
<td>$3.07</td>
<td>12.32%</td>
</tr>
<tr>
<td>Gilead Sciences Inc</td>
<td>102.32</td>
<td>5.71</td>
<td>3.78</td>
<td>9.01%</td>
<td>$2.98</td>
<td>$5.41</td>
<td>5.36%</td>
</tr>
<tr>
<td>Biogen Inc</td>
<td>24.92</td>
<td>1.81</td>
<td>2.98</td>
<td>3.75%</td>
<td>$0.92</td>
<td>$1.92</td>
<td>0.36%</td>
</tr>
<tr>
<td>Genmab AS</td>
<td>20.81</td>
<td>3.60</td>
<td>6.06</td>
<td>4.44%</td>
<td>$2.15</td>
<td>$5.21</td>
<td>29.58%</td>
</tr>
<tr>
<td>United Therapeutics Corp</td>
<td>15.74</td>
<td>2.68</td>
<td>6.44</td>
<td>5.04%</td>
<td>$0.39</td>
<td>$0.64</td>
<td>19.85%</td>
</tr>
<tr>
<td>Biomarin Pharmaceutical Inc</td>
<td>53.89</td>
<td>2.56</td>
<td>5.34</td>
<td>2.07%</td>
<td>$0.16</td>
<td>$0.58</td>
<td>19.61%</td>
</tr>
<tr>
<td>Incyte Corp</td>
<td>158.93</td>
<td>4.19</td>
<td>3.78</td>
<td>-10.6%</td>
<td>$-0.37</td>
<td>$0.97</td>
<td>9.34%</td>
</tr>
<tr>
<td>Neurocrine Biosciences Inc</td>
<td>36.10</td>
<td>4.82</td>
<td>5.81</td>
<td>2.66%</td>
<td>$0.16</td>
<td>$0.58</td>
<td>30.37%</td>
</tr>
<tr>
<td>Sarepta Therapeutics Inc</td>
<td>166.68</td>
<td>11.07</td>
<td>8.12</td>
<td>0.63%</td>
<td>$0.03</td>
<td>$0.32</td>
<td>38.93%</td>
</tr>
<tr>
<td>Roivant Sciences Ltd</td>
<td>2.09</td>
<td>1.63</td>
<td>63.42</td>
<td>1.67%</td>
<td>$0.09</td>
<td>$0.05</td>
<td>154.96%</td>
</tr>
<tr>
<td>Halozyme Therapeutics Inc</td>
<td>24.15</td>
<td>27.27</td>
<td>9.34</td>
<td>39.91%</td>
<td>$0.14</td>
<td>$0.19</td>
<td>4.67%</td>
</tr>
<tr>
<td>Average</td>
<td>57.77</td>
<td>8.33</td>
<td>10.88</td>
<td>6.45%</td>
<td>$0.95</td>
<td>$2.01</td>
<td>28.79%</td>
</tr>
</tbody>
</table>
<style>
 table {
 width: 100%;
 border-collapse: collapse;
 font-family: Arial, sans-serif;
 font-size: 14px;
 }

 th, td {
 padding: 8px;
 text-align: left;
 }

 th {
 background-color: #293a5a;
 color: #fff;
 text-align: left;
 }

 tr:nth-child(even) {
 background-color: #f2f4f8;
 }

 tr:hover {
 background-color: #e1e4ea;
 }

 td:nth-child(3), td:nth-child(5) {
 text-align: left;
 }

 .dividend-amount {
 font-weight: bold;
 color: #0d6efd;
 }

 .dividend-frequency {
 font-size: 12px;
 color: #6c757d;
 }
 </style>Through a detailed examination of AbbVie, we can deduce the following trends: 
<ul>
<li>
The Price to Earnings ratio of 64.53 for this company is 1.12x above the industry average, indicating a premium valuation associated with the stock.
</li>
<li>
It could be trading at a premium in relation to its book value, as indicated by its Price to Book ratio of 50.28 which exceeds the industry average by 6.04x.
</li>
<li>
With a relatively low Price to Sales ratio of 6.22, which is 0.57x the industry average, the stock might be considered undervalued based on sales performance.
</li>
<li>
The company has a higher Return on Equity (ROE) of 18.4%, which is 11.95% above the industry average. This suggests efficient use of equity to generate profits and demonstrates profitability and growth potential.
</li>
<li>
The company exhibits higher Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $5.0 Billion, which is 5.26x above the industry average, implying stronger profitability and robust cash flow generation.
</li>
<li>
Compared to its industry, the company has higher gross profit of $10.26 Billion, which indicates 5.1x above the industry average, indicating stronger profitability and higher earnings from its core operations.
</li>
<li>
The company's revenue growth of 4.31% is significantly below the industry average of 28.79%. This suggests a potential struggle in generating increased sales volume.
</li>
</ul>
<h3>Debt To Equity Ratio</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726758052_0.png" alt="debt to equity" />
The debt-to-equity (D/E) ratio helps evaluate the capital structure and financial leverage of a company.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
When assessing AbbVie against its top 4 peers using the Debt-to-Equity ratio, the following comparisons can be made:
<ul>
<li>
When evaluating the debt-to-equity ratio, AbbVie is in the middle position among its top 4 peers.
</li>
<li>
The company maintains a moderate level of debt relative to its equity with a debt-to-equity ratio of 10.42, suggesting a relatively balanced financial structure.
</li>
</ul>
<h3>Key Takeaways</h3>
For AbbVie, the PE, PB, and PS ratios are all high compared to its peers in the Biotechnology industry, indicating potentially overvalued stock. On the other hand, AbbVie's high ROE, EBITDA, and gross profit suggest strong profitability and operational efficiency relative to industry peers. However, the low revenue growth rate may raise concerns about the company's future performance compared to its competitors in the sector.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Competitor Analysis: Evaluating AbbVie And Competitors In Biotechnology Industry

Ripple Therapeutics Announces Collaboration And Option-To-License Agreement With AbbVie To Develop Biodegradable Sustained Release Drug Delivery Implants For Glaucoma Management

On CNBC's <a href="https://www.cnbc.com/video/2024/09/16/final-trades-transdigm-bjs-wholesale-abbvie-and-the-smh.html">&#8220;Halftime Report Final Trades</a>,&#8221; Stephen L. Weiss of Short Hills Capital Partners recommended buying TransDigm Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDG#NYSE">TDG</a>).
On Aug. 6, TransDigm Group reported better-than-expected third-quarter financial results and raised its FY24 guidance above estimates.
Jason Snipe of Odyssey Capital Advisors said BJ&#8217;s Wholesale Club Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BJ#NYSE">BJ</a>) beat on the bottom line.
On Aug. 22, BJ&#8217;s Wholesale reported better-than-expected second-quarter financial results. Revenue growth of 4.9% Y/Y to $5.205 billion, beating the analyst consensus estimate of $5.145 billion. Total comparable club sales increased by 3.1%. Comparable club sales, excluding gasoline sales, increased by 2.4%.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Anastasia Amoroso of iCapital picked VanEck Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NASDAQ">SMH</a>), saying semiconductor space is down 17%, so it's a good place to add.
Joe Terranova of Virtus Investment Partners named AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) as his final trade.
On Sept. 10, AbbVie&#8217;s CONSTELLA received Health Canada approval for treating childhood constipation. &#8220;Constipation is a common issue in childhood that can significantly impact a child&#8217;s quality of life and cause considerable stress for their families. These children and families will be grateful to have a new prescription treatment option that can offer symptom relief and improve the overall well-being of the child and family, making daily life more manageable,&#8221; said Dr. Melanie Schmidt, Division of Paediatric Gastroenterology and Hepatology at Children&#8217;s Hospital in London, Ontario.
Price Action:
<ul>
<li>TransDigm gained 0.4% to close at $1,372.92 during Monday's session.</li>
<li>BJ&#8217;s Wholesale shares fell 1.1% to settle at $80.57 on Monday.</li>
<li>VanEck Semiconductor ETF fell 1.3% during Monday's session.</li>
<li>AbbVie shares gained 0.8% to settle at $195.73 during Monday's session.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/40877520/if-you-want-steel-you-do-nucor-says-cramer-when-asked-about-gerdau">&#8216;If You Want Steel, You Do Nucor,&#8217; Says Cramer When Asked About Gerdau</a></li>
</ul>
Image generated using artificial intelligence via Midjourney.

Long Ideas

Media

TransDigm, BJ's Wholesale, AbbVie And More On CNBC's 'Final Trades'

CNBC Halftime Report Final Trades: Taiwan Semiconductor Manufacturing, AbbVie, BJ's Wholesale Club Holdings, VanEck Semiconductor ETF

UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) reportedly announced on Tuesday that it will remove AbbVie Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) blockbuster drug Humira from some of its preferred reimbursement lists starting January 1, 2025. The company will recommend lower-cost biosimilar versions instead.
This move is part of a larger trend in the U.S. pharmaceutical market, as health plans seek to cut costs by promoting alternatives to high-priced drugs.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/24/07/39695378/ftc-investigation-uncovers-anti-competitive-practices-by-handful-of-pharmacy-benefit-managers-includ" rel="noreferrer noopener">FTC Investigation Uncovers Anti-Competitive Practices By Handful Of Pharmacy Benefit Managers, Including CVS Health, UnitedHealth</a>.
Reuters highlights that Amgen Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) Amjevita, managed by its pharmacy benefits unit, Optum Rx, is among the biosimilars covered under UnitedHealth&#8217;s lists for commercial health plans.
With this decision, Optum becomes the last of the three largest U.S. pharmacy benefit managers (PBMs) to exclude Humira.
Cigna Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) announced last month that it would remove Humira from some of its lists in 2025, following a similar decision by CVS Health Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) Caremark unit in April.
CVS&#8217;s action led to a swift shift, with more patients transitioning to Sandoz Group AG&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SDZNY#OTC">SDZNY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SDZXF#OTC">SDZXF</a>) biosimilar version of Humira in just three weeks than in the previous 15 months combined.
Cigna plans to cover biosimilars like Boehringer Ingelheim&#8217;s Cyltezo, Simlandi from Teva Pharmaceutical Industries Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), and Alvotech&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVO#NASDAQ">ALVO</a>) products, including an unbranded version of Sandoz&#8217;s Hyrimoz, as replacements for Humira.
UnitedHealth noted that patients would still have access to Humira until the FDA designates the preferred biosimilars as interchangeable with the original drug, per the report. The FDA is expected to make this designation in 2025.
Despite the growing competition, AbbVie has managed to retain a dominant share of the U.S. Humira market throughout 2023. This has been achieved through favorable negotiations with PBMs, even as biosimilar alternatives from companies like Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) entered the market.
As per a Reuters report, Humira has still managed to retain over 80% of its patients even after facing lower-priced rivals in the&nbsp;<a target="_blank" href="https://www.benzinga.com/news/large-cap/24/04/38468317/arthritis-patients-cignas-evernorth-to-offer-humira-biosimilar-at-no-out-of-pocket-cost" rel="noreferrer noopener">U.S. over the past year</a>.
Following their launch last year, pharmacy benefit managers largely influenced patient access, with minimal incentive for doctors to switch to <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39228916/abbvies-arthritis-drug-humira-retains-market-dominance-despite-biosimilar-competition-challenges-" rel="noreferrer noopener">these alternatives</a>.
In May, Cantor Fitzgerald said AbbVie had positioned itself to absorb Humira biosimilar erosion and achieve modest <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38899905/abbvie-is-successfully-positioned-to-absorb-humira-biosimilar-erosion-analyst" rel="noreferrer noopener">operational revenue growth</a>.
Price Action: UNH stock is down 2% at $587.07 at last check Wednesday.
Photo via Shutterstock
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40817991/gsk-halts-herpes-simplex-virus-vaccine-development-clears-path-for-other-contenders-like-moderna-" target="_blank" rel="noreferrer noopener">GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech</a>.</li>
</ul>

Equities

ALVO

AMGN

SDZNY

SDZXF

TEVA

UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars

Investors with a lot of money to spend have taken a bullish stance on AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ABBV, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 13 options trades for AbbVie.
This isn't normal.
The overall sentiment of these big-money traders is split between 46% bullish and 46%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $33,000, and 12, calls, for a total amount of $817,396.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $155.0 to $200.0 for AbbVie over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in AbbVie's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to AbbVie's substantial trades, within a strike price spectrum from $155.0 to $200.0 over the preceding 30 days.
<h3>AbbVie Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726075892_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$16.9</td>
<td>$16.85</td>
<td>$16.85</td>
<td>$180.00</td>
<td>$337.0K</td>
<td>676</td>
<td style="text-align: right;">200</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$3.3</td>
<td>$3.25</td>
<td>$3.25</td>
<td>$200.00</td>
<td>$109.1K</td>
<td>2.4K</td>
<td style="text-align: right;">520</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$21.9</td>
<td>$20.75</td>
<td>$21.95</td>
<td>$175.00</td>
<td>$52.6K</td>
<td>2.9K</td>
<td style="text-align: right;">111</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$21.95</td>
<td>$21.6</td>
<td>$21.72</td>
<td>$175.00</td>
<td>$52.1K</td>
<td>287</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$15.1</td>
<td>$15.05</td>
<td>$15.1</td>
<td>$185.00</td>
<td>$37.7K</td>
<td>3.1K</td>
<td style="text-align: right;">88</td>
</tr>
</tbody>
</table>

<h3>About AbbVie</h3>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
<h3>Present Market Standing of AbbVie</h3>
<ul>
<li>Currently trading with a volume of 1,562,326, the ABBV's price is down by -1.93%, now at $195.5. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 44 days.</li>
</ul>
<h3>Professional Analyst Ratings for AbbVie</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $209.0.
<ul>
<li>An analyst from Piper Sandler has decided to maintain their Overweight rating on AbbVie, which currently sits at a price target of $209. </li>
</ul>
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for AbbVie with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

What the Options Market Tells Us About AbbVie

AbbVie's Allergan Aesthetics Launches BOTOX Cosmetic For Masseter Muscle Prominence In Adults In China

The City of Baltimore, led by Mayor Brandon M. Scott, reached an $80 million settlement with Teva Pharmaceuticals Industries Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) to resolve claims against the company for its role in the city&#8217;s opioid epidemic.
Under the agreement, Teva will pay an initial $35 million by the end of 2024, with the remaining amount due by July 1, 2025.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40754258/jp-morgan-shows-most-interest-in-teva-organon-as-specialty-pharma-sector-exhibits-s" rel="noreferrer noopener">JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability</a>.
The <a target="_blank" href="https://mayor.baltimorecity.gov/news/press-releases/2024-09-09-city-baltimore-reaches-80-million-deal-teva-pharmaceuticals-resolve" rel="noreferrer noopener">settlement</a> is part of Baltimore's broader litigation strategy against opioid manufacturers and distributors.
Previous settlements with AbbVie Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) Allergan, CVS Health Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), and Cardinal Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) have brought in $322.5 million in total recoveries.
The ongoing legal battle will proceed to trial on Sept. 16 against the remaining defendants, who were responsible for more than half of the opioids distributed in Baltimore.
Mayor Scott emphasized the city's decision to opt out of the national Teva settlement, which would have yielded only $11 million over 13 years. Instead, the new agreement brings in more than seven times that amount in under a year.
Baltimore secured more than three times the funds it would have received from global settlements.
Baltimore will dedicate $5 million to education and outreach about the 988 crisis helpline, $3 million to the Penn North Recovery Center and $2 million to BMore Power.
Additional funds will be administered following the framework detailed in the executive order to address the ongoing epidemic.
In July, Teva announced topline results from its Phase 3 SPACE study evaluating the efficacy of Ajovy (fremanezumab) for the prevention of episodic migraine in children and adolescent <a href="https://www.benzinga.com/general/biotech/24/07/39843370/tevas-migraine-treatment-found-effective-for-children-as-young-as-6" target="_blank" rel="noreferrer noopener">patients aged 6-17</a>.
The trial met its primary endpoint with Ajovy achieving a statistically significant superior efficacy over 12 weeks of treatment compared to placebo.
TEVA Price Action: Teva stock is down 1.43% at $17.55 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40793504/viridian-therapeutics-discloses-exciting-data-from-experimental-thyroid-eye-disease-candidate-say" target="_blank" rel="noreferrer noopener">Viridian Therapeutics Discloses &#8216;Exciting&#8217; Data From Experimental Thyroid Eye Disease Candidate, Says Data Met High Bars For Efficacy, Safety</a>.</li>
</ul>
Photo: Ralf Liebhold via Shutterstock

Legal

Teva Announces $80M Settlement To Baltimore: City Continues Opioid Litigation Against Other Companies

UnitedHealth Group Says It Will Remove AbbVie's Blockbuster Rheumatoid Arthritis Drug Humira From Some Of Its Lists Of Preferred Drugs For Reimbursement As Of Jan. 1, 2025, And Recommend Less Expensive Biosimilar Versions Of The Medicine Instead

Unitedhealth Says It Will Remove Abbvie's Humira From Some U.S. Drug Reimbursement Lists Next Year

My Dividend Stock Portfolio: New August Dividend Record - 101 Holdings With 17 Buys

DTD: Outperforming Its Peers In 2024, But SCHD Still Looks Better

AbbVie Rinvoq shows effectiveness for atopic dermatitis in head and neck

Amgen stock slides 5% as analysts weigh in on drug study results

Amgen stock slides 5% as analysts weigh in on drug study results (update)

AbbVie Parkinson's disease therapy hits main goal in late-stage trial

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AbbVie (ABBV – Research Report), ACADIA Pharmaceutic...

Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), ACADIA Pharmaceuticals (ACAD)

AbbVie submits BLA for antibody-drug conjugate Teliso-V for NSCLC

Leerink Partners analyst David Risinger has maintained their neutral stance on ABBV stock, giving a Hold rating on September 13. David Risinger's r...

AbbVie's Parkinson's Drug Tavapadon: A Market Perform Rating Amidst Competitive Landscape and Clinical Trials

Bristol Cobenfy approval draws optimism from Street, though with caveats

AAPL

ACAD

AGNC

ALIZF

APLE

ARCC

ARGX

AVGO

BABA

BASFY

BMWYY

BXSL

CBAUF

CNTA

CSCO

CSWC

GAIN

GILD

GLAD

GOOD

GSBD

HTGC

INTC

ITOT

MAIN

MFIC

MSFT

NVDA

OBDC

OTSKF

OTSKY

REGN

RITM

SCHD

SEMHF

SHEL

STAG

STWD

UNIT

VONOY

ZLAB

Screenshot 2024-05-14 at 6.27.53 PM

BRTX

CYNO

BioRestorative Therapies (NASDAQ: BRTX) Announces Commercial Agreement With Cartessa, Further Expanding Into $75.46 Billion Aesthetics Market

Screenshot 2024-02-24 at 12.03.42 AM

AXSM

TNXP

New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain

Dividends

Press Releases

AbbVie Declares Quarterly Dividend

AbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO 2024, with New Data in Tumor Types with High Unmet Needs

Health Canada Approves AbbVie's CONSTELLA® (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients 6 to 17 Years of Age

Allergan Aesthetics Launches BOTOX® Cosmetic (onabotulinumtoxinA) for Masseter Muscle Prominence (MMP) in Adults in China

AbbVie Receives Positive CHMP Opinion for Mirvetuximab Soravtansine (ELAHERE®) for the Treatment of Certain Adult Ovarian Cancer

Empowering Women Entrepreneurs: 2024 BOTOX® (onabotulinumtoxinA) Cosmetic Grant Recipients Kick Off Crowdfunding Campaigns

New Analysis Demonstrates the Efficacy of RINVOQ® (upadacitinib) in Atopic Dermatitis with Varying Degrees of Severity in Head and Neck Involvement

AbbVie and SpinUp Foster Canadian Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award

AbbVie Announces Positive Topline Results from Phase 3 TEMPO-1 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease

AbbVie Submits Biologics License Application to the FDA for Telisotuzumab Vedotin (Teliso-V) in Previously Treated Non-Small Cell Lung Cancer

Comments

AbbVie

Notizie

Ultime notizie per AbbVie (NYSE:ABBV) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO